One Mind's Rising Star Awards Celebrates 20 Years of Funding Innovative Mental Health Research
One Mind is now actively accepting applications for the 2025 One Mind Rising Star Awards program. Since its founding, One Mind has supported the curiosity and drive of the most promising early career scientists, enabling stunning breakthroughs and launching their careers as leaders. In 2005, One Mind formalized this strategy, launching the Rising Star Awards program with the fundamental belief that investing in world-class early-career investigators pursuing innovative, high-risk, high-reward research would accelerate breakthroughs in mental health conditions and psychiatric disorders. This year, in celebration of its 20th anniversary, One Mind will award at least three Rising Star Awards, each providing a $300,000 research grant ($100,000 per year for three years).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250418446650/en/
Applications for the One Mind Rising Star Awards are now open. Apply today!
Over the last two decades, One Mind has awarded over $13 million to 48 Rising Star Awardees pushing the frontiers of mental health science through their research and leadership. Among our 48 Awardees are such luminaries as:
One Mind is honored to continue this tradition of supporting great science that is already making an impact on the lives of many. As a 501(c)3 nonprofit, One Mind receives generous philanthropic support from private donors, foundations, and corporate sponsors who make the One Mind Rising Star Awards possible. This year, with generous support from Bristol Myers Squibb and Burroughs Wellcome Fund, one awardee will receive the 'One Mind Bristol Myers Squibb Rising Star Award' and two awardees will receive the 'One Mind Burroughs Wellcome Fund Rising Star Award.'
In addition to the $300,000 research grant, this year's Awardees will gain exclusive access to the Rising Leaders Lab, a program designed to equip them with the skills, network, and opportunities to drive meaningful impact in neuroscience research and mental health. Through leadership training, networking, and executive coaching, they will develop expertise in media engagement, negotiation, communication, personal branding, and impactful leadership. Workshops, webinars, and one-on-one mentorship with subject-matter experts will further empower them to become thought leaders shaping the future of mental health.
The 2025 One Mind Rising Star Awards will support grant proposals spanning basic/preclinical, translational, and clinical research for psychiatric disorders. These include, but are not limited to, schizophrenia, bipolar disorder, depression, obsessive-compulsive disorder, eating disorders, post-traumatic stress disorder, anxiety disorders, and suicidality. Transdiagnostic investigations and research that bring us closer to precision psychiatry will be given special attention. Illustrative examples include metabolomics biomarkers, gut microbiome-brain interactions, psychedelics, closed-loop neurostimulation, (AI/ML)-based biomarkers, and predictive analytics-based models for evaluating risk or treatment efficacy.
Awardees will be selected through a rigorous evaluation process based on the scientific rigor, potential for impact, relevance, feasibility, and innovation of the proposed project, as well as the candidate's credentials, research productivity, and leadership potential.
Applications are now open! For more information, and to apply, visit our website at onemind.org/rising-star-awards. If you are interested in supporting an award, please contact One Mind Chief Development Officer, Tal Gerzon, at [email protected].
About One Mind™
One Mind is at the forefront of a transformative movement in mental health, delivering innovative solutions to address critical gaps in mental health research, care, workplace wellness, and public perception. Guided by science and lived experience, we fund groundbreaking research, accelerate innovation, enhance workplace wellness, and engage the public to reshape mental health care and awareness. With science as our cornerstone, and people at the heart of what we do, our programs are setting new standards for effective interventions and redefining the future of mental health.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250418446650/en/
One Mind,[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: NEUROLOGY MENTAL HEALTH HEALTH SCIENCE RESEARCH
SOURCE: One Mind
Copyright Business Wire 2025.
PUB: 04/18/2025 09:05 AM/DISC: 04/18/2025 09:06 AM
http://www.businesswire.com/news/home/20250418446650/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Successful Launch of Metop-SGA1 to Take Weather Forecasting to New Heights
BUSINESS WIRE)--With a global audience watching in anticipation at launch events and online, Metop Second Generation A1 (Metop-SGA1) – also carrying the European Union's Copernicus Sentinel-5 mission – lifted off on an Ariane-62 rocket from Europe's Spaceport in Kourou, French Guiana, at 02:37 CEST on 13 August. As the first satellite in the EUMETSAT Polar System – Second Generation (EPS-SG) programme, the launch marks a major step toward delivering more precise forecasts and earlier warnings to help protect lives and property from extreme weather. EPS-SG will also support economies across Europe, with an expected return on investment of at least 20 to 1. Now heading into a polar orbit around 800 kilometres above the Earth's surface, Metop-SGA1 will soon begin transmitting a wealth of timely, high-resolution and high-quality observations from six complementary instruments. These data will continue the Metop series of satellites' role as Europe's most important source of meteorological observations for forecasts ranging from 12 hours to 10 days ahead. For example, Metop-SGA1 observations will help meteorologists improve short- and medium-term weather models that can save lives by enabling early warnings of storms, heatwaves, and other disasters, and help farmers to protect crops, grid operators to manage energy supply, and pilots and sailors to navigate safely. Phil Evans, EUMETSAT Director-General, said: 'Extreme weather has cost Europe hundreds of billions euros and tens of thousands of lives over the past 40 years – storms like Boris, Daniel and Hans, record heatwaves and fierce wildfires are just the latest reminders. The launch of Metop-SGA1 is a major step forward in giving national weather services in our member states sharper tools to save lives, protect property, and build resilience against the climate crisis. These positive impacts will be felt even beyond that and over the Atlantic, as Metop-SGA1 is Europe's first contribution to the Joint Polar System with the United States' National Oceanographic and Atmospheric Administration (NOAA). This milestone reflects years of teamwork across EUMETSAT, the European Space Agency (ESA), the European Union, the French Space Agency (CNES), the German Aerospace Centre (DLR), Airbus, Thales Alenia Space, and many others. This is the beginning of an exciting new chapter as we work to ensure the satellite settles into orbit and starts delivering the vital data it was built to provide.' At the heart of better forecasts More than 95% of the data used in numerical weather prediction comes from satellites –a share set to grow as Metop Second Generation satellites enter service. Unlike geostationary spacecraft fixed above the equator, polar-orbiting satellites like Metop-SGA1 travel north to south as Earth rotates beneath them, delivering global coverage and a rich variety of observations. Over the next two decades, three consecutive pairs of Metop-SG satellites will loop the planet 14 times daily, with advanced instruments collecting high-resolution data on the atmosphere, oceans, ice sheets, and land surfaces. The Metop-SGA1 satellite hosts a total of six atmospheric sounding and imaging instrument missions. The payload includes the Infrared Atmospheric Sounding Interferometer – New Generation (IASI-NG), METimage (a visual and infrared imager), the Microwave Sounder (MWS), a Radio Occultation sounder, and the Multi-Viewing, Multi-Channel, Multi-Polarisation Imager (3MI) – the latter being an entirely new instrument designed to enhance the monitoring of aerosols and cloud properties. Metop-SGA1 also carries the European Union's Copernicus Sentinel-5 mission, which will supply detailed data on atmospheric composition and trace gases that affect air quality, helping health authorities to monitor air pollution. Christoph Kautz, Director for Space Policy, Earth Observation and Satellite Navigation at the European Commission, said: 'The successful launch of Copernicus Sentinel-5 is a testimony to our close cooperation with EUMETSAT and is an outstanding achievement that will strengthen Europe's capacity to monitor pollution and advance climate science. Thanks to the synergies with EUMETSAT's meteorological mission, it was decided to embark Sentinel-5 on Metop-SGA1. This joint approach not only optimises the overall mission costs but also lowers the environmental impact by minimising the number of launches required.'' Simonetta Cheli, Director of Earth Observation Programmes at ESA, said: 'Metop-SGA1 and Copernicus Sentinel-5 show the power of European collaboration in building long-term missions that help us take the pulse of our planet. This successful launch will ultimately give us an unprecedented view of our atmosphere and climate. The data will allow us to monitor air quality, track greenhouse gases, and observe clouds, trace gases and ozone in more detail than ever. By feeding these insights into models and tools, we can strengthen climate action, improve public health, and deliver benefits for communities across Europe and beyond.' For further updates on Metop-SGA1, visit EUMETSAT's launch hub, which features news, interviews, and insights into the satellite's journey. Find all relevant information, biographies of speakers, videos and testimonials on our dedicated press page. About EUMETSAT EUMETSAT, Europe's meteorological satellite agency, monitors the weather and climate from space. Based in Darmstadt, Germany, EUMETSAT provides its 30 member states with meteorological imagery and data that are essential for keeping their communities safe and for the benefit of critical sectors of their economies. For more information, see the EUMETSAT website.
Business Wire
an hour ago
- Business Wire
NTT DATA Partners with Google Cloud to Accelerate Agentic AI Adoption and Cloud Modernization for Enterprises Globally
TOKYO & LONDON--(BUSINESS WIRE)--NTT DATA, a global leader in digital business and technology services, today announced a global partnership with Google Cloud to accelerate AI-powered cloud innovations and unlock new possibilities with AI for enterprise organizations across industries. This collaboration combines NTT DATA's deep industry expertise in AI, cloud-native modernization and data engineering with Google Cloud's advanced analytics, AI and cloud technologies to deliver tailored, scalable enterprise solutions. With a focus on co-innovation, the partnership will drive industry-specific cloud and AI solutions, leveraging NTT DATA's proven frameworks and best practices along with Google Cloud's capabilities to deliver customized solutions backed by deep implementation expertise. Significant joint go-to-market investments will support seamless adoption across key markets. According to Gartner®, worldwide end-user spending on public cloud services is forecast to reach $723 billion in 2025, up from $595.7 billion in 2024. 1 The use of AI deployments in IT and business operations is accelerating the reliance on modern cloud infrastructure, highlighting the critical importance of this strategic global partnership. 'This collaboration with Google Cloud represents a significant milestone in our mission to drive innovation and digital transformation across industries,' said Marv Mouchawar, Head of Global Innovation, NTT DATA. 'By combining NTT DATA's deep expertise in AI, cloud-native modernization and enterprise solutions with Google Cloud's advanced technologies, we are helping businesses accelerate their AI-powered cloud adoption globally and unlock new opportunities for growth.' 'Our partnership with NTT DATA will help enterprises use agentic AI to enhance business processes and solve complex industry challenges,' said Kevin Ichhpurani, President, Global Partner Ecosystem at Google Cloud. 'By combining Google Cloud's AI with NTT DATA's implementation expertise, we will enable customers to deploy intelligent agents that modernize operations and deliver significant value for their organizations.' Driving AI innovation across industries NTT DATA will leverage Google Cloud technology to develop several industry-specific AI and cloud solutions, accelerating enterprise transformation across sectors including banking, insurance, manufacturing, retail, healthcare, life sciences and the public sector. For example, in financial services, this collaboration will support regulatory compliance and reporting through NTT DATA solutions like Regla, which leverage Google Cloud's scalable AI infrastructure. In hospitality, NTT DATA's Virtual Travel Concierge enhances customer experience and drives sales with 24x7 multilingual support, real-time itinerary planning and intelligent travel recommendations. It uses the capabilities of Google's Gemini models to drive personalization across more than 3 million monthly conversations. Key focus areas include: Industry-specific agentic AI solutions: NTT DATA will build new industry solutions that transform analytics, decision-making and client experiences using Google Agentspace, Google's Gemini models, secure data clean rooms and modernized data platforms. AI-driven cloud modernization: Accelerating enterprise modernization with Google Distributed Cloud for secure, scalable modernization built and managed on NTT DATA's global infrastructure, from data centers to edge to cloud. Next-generation application and security modernization: Strengthening enterprise agility and resilience through mainframe modernization, DevOps, observability, API management, cybersecurity frameworks and SAP on Google Cloud. Sovereign cloud innovation: Delivering secure, compliant solutions through Google Distributed Cloud in both air-gapped and connected deployments. Air-gapped environments operate offline for maximum data isolation. Connected deployments enable secure integration with cloud services. These scenarios meet data sovereignty and regulatory demands in sectors such as finance, government and healthcare without compromising innovation. Google Distributed Cloud sandbox environment: Google Distributed Cloud sandbox environment is a digital playground where developers can build, test and deploy industry-specific and sovereign cloud deployments. This sandbox will help teams upskill through hands-on training and accelerate time to market with Google Distributed Cloud technologies through preconfigured, ready-to-deploy templates. NTT DATA will support these innovations through a full-stack suite of services including advisory, building, implementation and ongoing hosting and managed services. By combining NTT DATA's proven blueprints and delivery expertise with Google Cloud's technology, the partnership will accelerate the development of repeatable, scalable solutions for enterprise transformation. At the heart of this innovation strategy is Takumi, NTT DATA's GenAI framework that guides clients from ideation to enterprise-wide deployment. Takumi integrates seamlessly with Google Cloud's AI stack, enabling rapid prototyping and operationalization of GenAI use cases. This initiative expands NTT DATA's Smart AI Agent Ecosystem, which unites strategic technology partnerships, specialized assets and an AI-ready talent engine to help clients deploy and manage responsible, business-driven AI at scale. Accelerating global delivery with a dedicated Google Cloud Business Group To achieve excellence, NTT DATA has established a dedicated global Google Cloud Business Group comprising thousands of engineers, architects and advisory consultants. This global team at NTT DATA will work in close collaboration with Google Cloud teams to help clients adopt and scale AI-powered cloud technologies. NTT DATA is also investing in advanced training and certification programs ensuring teams across sales, pre-sales and delivery are equipped to sell, secure, migrate and implement AI-powered cloud solutions. The company aims to certify 5,000 engineers in Google Cloud technology, further reinforcing its role as a leader in cloud transformation on a global scale. Additionally, both companies are co-investing in global sales and go-to-market campaigns to accelerate client adoption across priority industries. By aligning technical, sales and marketing expertise, the companies aim to scale transformative solutions efficiently across global markets. Building on strategic momentum This global partnership builds on NTT DATA and Google Cloud's 2024 co-innovation agreement in APAC. In addition it further strengthens NTT DATA's acquisition of Niveus Solutions, a leading Google Cloud specialist recognized with three 2025 Google Cloud Awards – 'Google Cloud Country Partner of the Year - India,' 'Google Cloud Databases Partner of the Year - APAC' and 'Google Cloud Country Partner of the Year – Chile,' further validating NTT DATA's commitment to cloud excellence and innovation. 'We're excited to see the strengthened partnership between NTT DATA and Google Cloud, which continues to deliver measurable impact. Their combined expertise has been instrumental in migrating more than 380 workloads to Google Cloud to align with our cloud-first strategy,' said José Luis González Santana, Head of IT Infrastructure, Carrefour. 'By running SAP HANA on Google Cloud, we have consolidated 100 legacy applications to create a powerful, modernized e-commerce platform across 200 hypermarkets. This transformation has given us the agility we need during peak times like Black Friday and enabled us to launch new services faster than ever. Together, NTT DATA and Google Cloud are helping us deliver more connected, seamless experiences for our customers,' About NTT DATA NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. 1 Gartner Press Release, Gartner Forecasts Worldwide Public Cloud End-User Spending to Total $723 Billion in 2025, November 19, 2024 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Yahoo
2 hours ago
- Yahoo
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development ("D&PD") to better reflect strategic focus Group revenues of € 371.2 m (-5%); D&PD (-11%) continues to see soft demand;Just - Evotec Biologics ("JEB"; +16%) exceeding expectations driven by broadened customer base Key progress in collaborations with Bristol Myers Squibb ("BMS") on targeted protein degradation and neuroscience Evolution of strategic partnership with Sandoz announced on 30 July HAMBURG, DE / / August 13, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced financial results for H1 2025, demonstrating clear progress in the implementation of its new strategy for sustainable and profitable growth; highlighting Just - Evotec Biologics' strong growth as it transitions to an asset-lighter model. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "We are firmly on track with the execution of our strategy: Evotec is making meaningful strides toward sustainable and profitable growth. JEB maintained its strong growth trajectory with first half revenues in excess of € 100 m, and the evolution of our strategic partnership with Sandoz is testament to its bright future as a scalable technology provider with a more capital-efficient model. Our base business in D&PD continues to face soft demand, but we see strong progress in core collaborations and are systematically expanding our platform technologies, such as our Molecular Patient Database. I am confident that our unrelenting focus on technology and science leadership will continue to drive tangible impact in the future". Discovery & Preclinical Development impacted by soft market; Just - Evotec Biologics continues strong growth momentum Group revenues decreased by 5.0% to € 371.2 m (6M 2024: € 390.8 m) Total D&PD revenues decreased by 11.0% to € 269.0 m (6M 2024: € 302.4 m) with performance reflecting soft drug discovery market environment and phasing of revenues with Pharma partners; recovery of D&PD market expected as early as 2026 Just - Evotec Biologics revenues increased by 16% to € 102.2 m (6M 2024: € 88.9 m); strong growth with non-Sandoz / non-DoD customers Adjusted Group EBITDA totalled € (1.9) m (6M 2024: € (0.5) m) in-line with expectations due to strong cost control across the business Execution of strategy to refocus and deliver sustainable profitable growth fully on track Cost savings expected to exceed targets announced during the Q1 2025 results call on 06 May 2025 Implementation of strategy and new organization initiated Events after Period-End On 30 July 2025, Evotec announced the signing of a non-binding agreement on the potential sale ofJust - Evotec Biologics EU - which owns the biologics manufacturing facility in Toulouse, France and to grant access to its proprietary platform for integrated development and advanced continuous manufacturing of biologics via a technology license Deal terms include purchase price of the site for around US$ 300 m in cash and additional further technology related consideration, future development revenues, milestones and product royalties Planned transaction validates JEB's end-to-end continuous manufacturing technology and marks milestone in planned transition of JEB to asset-lighter model that better scales and leverages its technology and IP Closing of the planned transaction remains subject to completion of the relevant information and consultation processes with employees and their representatives, final contractual agreements and to meeting regulatory requirements, expected in the fourth quarter Progress in key strategic collaborations Significant progress in strategic protein degradation collaboration with BMS triggering performance-based and program-based payments of in total US$ 75 m Key progress in neuroscience collaboration with BMS triggering a research payment of US$ 20 m Grant awarded from The Gates Foundation ("GF") to support the development of next-generation treatment regimens for tuberculosis ("TB") Evotec joined NURTuRE-AKI consortium, expanding Molecular Patient Database and improving leadership position in the field of kidney disease Evotec welcomed the FDA's "Roadmap to Reducing Animal Testing in Preclinical Safety Studies" which is aligned with Evotec's long-term strategic investment in New Approach Methodologies (NAMs) and its 30+ year commitment to ethics and the principles of 3-Rs (Replacement, Reduction and Refinement) Guidance for full-year 2025 Group revenues expected in a range of € 760 - 800 m (2024: € 797.0 m) R&D expenditures are expected in a range of € 40 - 50 m (2024: € 50.9 m) Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m) More detailed information and financial tables are available in the half-year report published on the Evotec website under the following link: Webcast/Conference Call The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English. Webcast details Date: Wednesday, 13 August 2025 Time: 2.00 pm CEST (1.00 pm BST, 8.00 am EDT) To join the audio webcast and to access the presentation slides, please register via this link. The on-demand version of the webcast will be available on our website: Financial Publications - Evotec . Conference call details To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call. A simultaneous slide presentation for participants dialing in via phone is available under this link. About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to and follow us on X/Twitter @Evotec and LinkedIn . Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations Volker BraunEVP Head of Global Investor Relations & SOURCE: Evotec SE View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
